Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Community sentiment
Where do you think SPTX is heading?
1 month
6 months
12 months
5 years
Keep private notes on SPTX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
SPTX vs S&P 500 · rebased to 100
▼ -57.1% / yr▼ 66.4 pts / yr vs S&P 500(S&P 500 +9.3% / yr)▼ 9.3% total
Compare:
Early cycleMid cycleLate cycleRecession
Background shading marks the US business-cycle phase at each point in time — early, mid and late expansion, then recession— so you can see which economic backdrop each move happened in. Recessions are NBER-official; expansion sub-phases are ActaClear's editorial dating.
Lines:
Overlay:
Live market
delayed ≤15 min$21.39
▲ 10.51%
- Market cap
- $1.15B
- Enterprise value
- $1.15B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $23.00
- 52-wk low
- $14.85
- Beta
- —
- Shares out
- 53.5M
What this company does
Not yet available for SPTX.
Key risks
Not yet available for SPTX.
8.8
of 10
ActaClear Score
Strong
#14 of 531 in Pharmaceutical Preparations
new
Profitability·25%
—
Growth·15%
—
Value·20%
—
Quality·20%
—
Momentum·20%
8.8
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (531 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 28, 2026.